Biotech Firm CytoMed Opens New Investment Opportunity with SEC Registration

Rhea-AI Filing Summary

CytoMed Therapeutics has received Notice of Effectiveness from the SEC for its Form F-3 registration statement (File No. 333-288033), effective as of June 23, 2025, at 4:00 P.M.

Form F-3 is a securities registration statement used by foreign companies that are already listed on a U.S. exchange and meet certain eligibility requirements. This effectiveness notice indicates that CytoMed can now proceed with its planned securities offering as outlined in the registration statement.

The effectiveness of this F-3 filing suggests that CytoMed may be planning to:

• Raise additional capital through securities offerings
• Register securities for potential future offerings
• Enhance its financial flexibility for future growth initiatives

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	June 23, 2025 4:00 P.M.

Form:

F-3

CIK:	0001873093
Company Name:	CytoMed Therapeutics Ltd
File Number:	333-288033

FAQ

What type of SEC filing did GDTC submit that became effective on June 23, 2025?

GDTC (CytoMed Therapeutics Ltd) submitted a Form F-3 registration statement that became effective on June 23, 2025 at 4:00 P.M. The Form F-3 is a registration statement for foreign companies to register various types of securities.

When did GDTC's Form F-3 registration statement become effective?

CytoMed Therapeutics Ltd's (GDTC) Form F-3 registration statement became effective on June 23, 2025 at 4:00 P.M., as confirmed by the SEC's Notice of Effectiveness.

What is GDTC's CIK number for SEC filings?

CytoMed Therapeutics Ltd's (GDTC) CIK number is 0001873093, as shown in the SEC's Notice of Effectiveness filing.

What is the file number for GDTC's Form F-3 registration statement?

The file number for CytoMed Therapeutics Ltd's (GDTC) Form F-3 registration statement is 333-288033, as indicated in the SEC filing.